Curriculum Vitae
Thomas J. Smith, M.D., F.A.C.P.
1
1.1
1.2
1.3
1.4
Personal Information
Name:
Born
Citizenship:
Marital Status:
1.4.1 Children:
1.5
Home Address:
Thomas J. Smith, M.D., F.A.C.P.
Cuyahoga Falls, Ohio, U.S.A. September 19, 1952
USA
Married, Joann Norma Bodurtha, M.D., MPH; Associate Professor
of Human Genetics, Pediatrics, and Obstetrics/Gynecology
Anna Jo Bodurtha Smith, born July 14, 1988
14219 Hickory Oaks Lane, Ashland, Virginia 23005,
(804)-798-5730
Medical College of Virginia at Virginia Commonwealth
University, Division of Hematology, 1101 East Marshall Street,
PO Box 980230, Richmond, VA 23298-0230. E mail
[email protected]
1.6
Business Address:
2
2.1.1
2.1.2
2.1.3
2.1.4
Licensure
Virginia 0101037893
DEA AS2593312
NCI Investigator No. 09961
ACLS Provider April 2001-3
2.2
2.3
2.4
2.5
Board Certification
ELNEC Certification, July 24-27, 2007
Hospice and Palliative Care Medicine, February 2003-2013.
Advanced Cardiac Life Support Provider Renewal, Center for Trauma and Critical Care,
April 7, 2001
Hematology, 1990-2000
Medical Oncology, 1987Internal Medicine, 1982-
2.6
2.7
2.8
3
3.1
3.3
3.4
3.5
3.6
Education
Medical College of Virginia-Virginia Commonwealth University Fellowship in
Hematology/Oncology 1982- 1987, Board certified in 1987; 1990.
Special Visiting Fellow, National Cancer Center Biological Response Modifiers Program,
Frederick, MD 1986
Yale University School of Medicine, M.D. cum laude 1974-79
Yale University School of Organization and Management (core curriculum)1977-78
University of Akron, B.S., summa cum laude 1971-74
Ohio Governor's School, Fellowship in Management 1971
4
Military Service Record: None
5
Postdoctoral Training
3.2
5.1
5.2
Faculty Scholar, Program on Death in America, Open Society, New York 1995-9
Special Fellow in Medical Oncology, National Cancer Institute, NCI-BRMP, Frederick,
MD 1986
5.2.1 Fellow in Hematology/Oncology, Medical College of Virginia, Richmond, VA 1984-89
5.2.2 Residency in Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA,
1979-82
6
6.1
6.2
6.3
6.4
6.5
6.6
6.7
6.8
6.9
6.10
6.11
6.12
6.13
6.14
6.15
6.16
6.17
6.18
7
7.1
7.2
7.3
7.4
7.5
7.6
7.7
7.8
Academic Appointments or Other Significant Work Experience
2002- Esteemed Professor of Medicine (oncology), VCU
2001-5 Institute of Medicine National Cancer Policy Board
1999- Chair, Division of Hematology/Oncology
1999- Clinical Oncology Services Committee, MCVH
1999- Professor, Medicine and Health Administration
1999- Medical Director, Thomas Hospice Palliative Care Unit, MCVH
1998 Clinical Practice Guidelines Committee Panel, MCVH
1998- Advisory Board, Thomas Hospice/Palliative Care Unit at MCVH
1997- Group Leader, Albert Schweitzer Institute for the Humanities, Continuing
Medical Education in Kyrgyzstan
1997- MCVH Hospice Working Group Leader
1995-9 Associate Professor of Medicine and Health Administration
1995- Physician, Cross-Over Health Ministry, Richmond, Virginia
1995-8 Chairman, American Society of Clinical Oncology Health Service Research
Committee; $250,000 annual budget.
1995-7 Vice-Chair, Cancer and Leukemia Group B Economics and Outcomes Research
Subcommittee
1994-7 MCV Hospitals/Mercer Management Corporation Re-engineering Project.
Charged with reducing oncology pharmacy costs by 20% in 3 years
1992- Director of Cancer Education, Massey Cancer Center
1992- Associate Member, Williamson Institute of Health Economics
1990- Assistant Professor of Medicine & Health Administration
Membership - Scientific, Honorary and Professional Societies
Member, ASCO Cost of Cancer Care Task Force, August 2007Member, ASCPRO “Assessing the symptoms of cancer using patient related outcomes”
Advisory Panel to the FDA, Charles Cleeland, PI
National Cancer Institute of Canada's Health Economics, Services, Policy, and Ethics
(HESPE) Cancer Research Centre Planning Committee, April 2007ASCO Quality Oncology Practice Initiative Best Practices Work Group 2006Reviewer, Belgian Cancer Society, 2006RAND Technical Panel, Quality Measures at end of life, Karl Lorenz, PI, 2006MGH-Partners Technical Advisory Panel for End of Life benchmarks, Jennifer Hass MD,
PI, 2006Chair, American Society of Clinical Oncology Expert Panel, White Cell Growth Factors,
2005-6.
2
7.9
Member, American Society of Clinical Oncology Expert Panel, Breast Cancer
Surveillance, 2005-6.
7.10 Chair, National Quality Forum Project on Hospital Guidelines for Symptom Management
and End of Life Care, 2004-.
7.11 National Consensus Project Advisory Council Project on Quality Palliative Care:
Essential Elements and Best Practices 2002-4
7.12 External Reviewer, NCI CanCORS cancer surveillance program, 2002-6
7.13 American Society of Clinical Oncology Program Committee 2001-3
7.14 National Marrow Donor Program Optimal Size Registry Analysis Expert Panel 2000-5
7.15 American Cancer Society Grant Review Committee 2001-5
7.16 American Society of Clinical Oncology
7.16.1 Member (with RAND, Komen Foundation, Harvard School of Public Health) National
Initiative on Cancer Care Quality 19997.16.2 Chairman, Committee on Health Service Research 1994-98
7.16.3 Committee for Health Service Research - 1999-01
7.17 Board of Editors, Journal of Clinical Oncology - 1995-98
7.18 Co-chair, Guidelines Review Panel on use of hematopoeitic growth factors - 1998-00
7.19 Director, ASCO Curriculum on Palliative Care, 19997.20 Member, ASCO Working Group on Guidelines Evaluation
7.21 Member, Expert Panel on Use of Tamoxifen/Raloxifene for Breast Cancer Prevention
1999
7.22 Member, Task Force on Improving Care at the End of Life
7.23 Member, Task Force on Managed Care
7.24 Member, Expert Panel to Determine Outcomes that Justify Cancer Treatment
7.25 Member, Expert Panel on Hematopoietic Growth Factors
7.26 Member, Expert Panel on Non Small Cell Lung Cancer Treat
7.27 Member, Expert Panel on Breast Cancer follow up care
7.28 Member, Expert Panel on Colorectal Cancer follow up care
7.29 Member, Expert Panel on Tumor Markers
7.30 Member, Expert Panel on Unresectable Prostate Cancer Care
7.31 Editor, Colorectal Cancer Follow up Care Guidelines
7.32 American Medical Association
7.33 Fellow, American College of Physicians
7.34 American Association for the Advancement of Science
7.35 Virginia Society of Hematology/Oncology, President, 1989-90
7.36 Virginia Hematology/Oncology Association 19947.37 American Association for Cancer Education 1986-92
7.38 Cancer and Leukemia Group B
7.39 Vice-Chairman, Economics Committee - 1997 -2000
7.40 Liason, Leukemia Committee - 1998-01
7.41 National Surgical Adjuvant Breast and Bowel Cancer Program
7.42 American Society for Blood and Marrow Transplantation
7.43 European Society for Medical Oncology 1998-
7.44
Multinational Association for the Study of Supportive Care in Cancer
8
8.1
8.2
8.3
8.4
8.5
8.6
Membership in Community Organizations
2007- Member, Chris Desch Foundation Board
2004- Ashland Friends of the Library Board
2000- Salvation Army Boys and Girls Clubs Camp Happyland summer camp physicals
1995-99 Board of Directors, American Cancer Society, Hanover County Unit
1994- Physician, Cross-Over Free Health Clinic, Richmond, VA
1994- Director of Cancer Palliative Care Programs, American Medical Teams for
Africa, World Health Organization/American Medical Teams for Africa Cancer
Pain Relief Programme, Tanzania-Zanzibar
1991-2 Childrens Story Hour Reader, Pamunkey Regional Library, Hanover County
1985-7 Co-coordinator, Ashland Mountain of Trash (community cleanup and recycling)
1984- Richmond Friends Meeting, Richmond, VA
8.7
8.8
8.9
9
9.1
9.2
9.3
9.4
9.5
9.6
9.7
9.8
9.9
9.10
9.11
9.12
9.13
9.14
9.15
9.16
9.17
9.18
Special Awards, Fellowships, and Other Honors
Oncology Nursing Society Grant to teach End of Life Care Nursing Education
Consortium (ELNEC) course, Dar es Salaam, Tanzania July 2007
ASCO IDEA Mentor for Developing Countries, Dr. Sani Malani, Nigeria, June 2007
ASCO Annual Prostate Cancer Meeting Special Lecture: “Can we afford our progress?”
February 24, 2007
Co-Chair, Supportive Care Congress, NYC February 23-5, 2007
MacMillan Fund UK Plenary Lecturer: NCRI Annual Conference, Birmingham, UK
October 7, 2006.
Dutch Cancer Society External Grant Reviewer, 2006.
Chair, ASCO Annual Meeting, Clinical Problems in Oncology Session “Getting savvy
with opioids to manage cancer pain: routes, rotations, interventions.” June 2006
Project ASSIST, RAND Corporation, 2006Project DeCIDE, Technical Advisory Panel for End-of-Life Benchmarks, MGH-Partners,
2006VCU Outstanding Teacher Award, Hematology/Oncology M-2 course, August 2006
Jonathon Gold “Humanism in Medicine” Charter Club, 2006
International Association of Hospice and Palliative Care University Award to best
university based palliative care program 2006
Faculty Award for Distinguished Clinical Care, VCU Medical Center Department of
Medicine 2006
American Hospital Association “Circle of Life” award to best hospital based palliative
care program
Master Trainer, EPEC-O for oncologists 2005Top Doctors in America: Oncology 2001-7
“Top doctors in Richmond: Oncology” Richmond Magazine, Richmond Academy of
Medicine 2001-6
“America’s Top Doctors: Medical Oncology,” Castle Connelly 2001-7
9.19
9.20
9.21
9.22
9.23
9.24
9.25
9.26
9.27
9.28
9.29
9.30
9.30.1
9.30.2
9.30.3
9.30.4
9.30.5
9.30.6
9.30.7
Outstanding Teacher Certificate, M-II course, 2002-3, awarded October 2003.
John Eric Olson MD Visiting Lecturer and Professor, Bassett Health Care Cancer Center,
Cooperstown, New York, April 17-8, 2003
Dale O. Ham MD Visiting Professor, Case Western Reserve University Ireland Cancer
Center, Cleveland Ohio February 7, 2003
Alpha Omega Alpha Medical Honor Society, Brown Sequard Chapter, May 2002.
“National Top Breast Cancer Doctors” Redbook Magazine, September 2001.
Salvation Army Boys and Girls Clubs Community Outreach Award, 2001
Best Doctors in Richmond: “Top medical specialists for women: breast cancer, breast
diseases” Richmond Magazine, 2001
MCV-VCU “Distinguished Clinician Award” as the outstanding clinician in practice at
the medical center. May 13, 2000
Best Doctors in Richmond, “Oncology”, Richmond Magazine 2000
National “Humanism in Medicine Award” for “embodying compassion and sensitivity in
the delivery of care to patients and their family members.” May 13, 2000. New Jersey
Health Care Foundation.
“Pioneer in Palliative Care” program designee, Robert Wood Johnson Foundation and
Milbank Memorial Fund, 2000-2001.
Best Physicians in Richmond, Virginia (Oncology), Richmond Magazine, 1999
Jessie Ball duPont Fund Making a Difference Award for “creation of a program which
meets a critical societal need” (Rural Cancer Outreach Program) 1996
Sharon H. Kohlenberg Health care Service Award, for “commitment to the fight against
breast cancer”, Virginia Breast Cancer Foundation, 1995
Scholarship Award in Patient-Physician Communications, Department of Human
Genetics, Medical College of Virginia (used patent royalties to create this endowment)
Fellow, American College of Physicians, 1992
Outstanding Alumni, Chippewa Local High School, Doylestown, Ohio, 1992
Outstanding Paper (Dr. Bruce Hillner, coauthor), Society of Medical Decision-Making,
1991
Best Teacher, Department of Internal Medicine, 1989.
9.31 Fellowships
9.31.1 Visiting Professor in Palliative Care and Oncology, McGill University/University of
Montreal/ Institute for Clinical Research, Montreal, Quebec, Canada, November 1998
9.31.2 Pfizer Traveling Fellowship Award, Clinical Research Institute of Montreal, Montreal,
P.Q. March 1996
9.32 External Grants
9.32.1 NLM GO8 (RO1) Smith T (PI), with Khatcheressian J, Lyckholm L, Matsuyama R;
consultants Crawford J, Siminoff L, Schrag D, Loprinzi C, Tannock I. Provision of
honest, accurate helpful information on the Internet for patients about prognosis,
treatment efficacy, and treatment decisions of breast, colorectal, lung, and prostate cancer.
Goal: improve cancer treatment decisions in cancer patients by provision of honest
information about prognosis, treatment options, treatment efficacy and side effects. Role:
PI. 20% effort and salary
9.32.2 R01CA116227-01 (Meier). Morrison S, Meier D, Smith T, et al. (9/29/06 approved for
funding ; 5 years) Impact of palliative care on outcomes of hospitalized patients. Six
center study; site PI. Goal: assess the impact of palliative care consultation on health and
economic outcomes of hospitalized sick inpatients at 6 major hospitals. Role: Site PI.
10% effort and salary.
9.32.3 JEHT Foundation, New York, New York. Continuation grant for CAPC Palliative Care
Leadership Center, $375,000/3 years (to match other program funding.)
9.32.4 Robert Wood Johnson/Center to Advance Palliative Care National Center of Excellence
for Palliative Care Education, 7/1/03-6/31/06. $750,000. 20% effort and salary.
9.32.5 American Cancer Society. Targeted Cost-Effectiveness Assessments in Cancer. PI Hillner
BE. 01/01/04 to 12/31/07, 2.5% effort/salary, $143,125
9.32.6 Commonwealth of Virginia. Virginia Initiative for Palliative Care (VIPC). 11/05-present.
$100,000/year. Train Virginia health care professionals in palliative care.
9.32.7 The goal is to provide objective, non-commercial CEA’s for high cost technology, such
as monoclonal antibody therapy.
9.32.8 VistaCare Foundation. Randomized trial of nebulized fentanyl vs placebo for dyspnea. PI,
Tom Smith. $10,000. 7.1. 03, one year.
9.32.9 American Cancer Society, Targeted Cost effectiveness Assessments in Cancer
Treatments. Bruce Hillner, PI; Tom Smith, Investigator, 2.5%, 1.1.04 to 12.31.07.
9.32.102002-5 NCI Core Grant for Massey Cancer Center: co-leader, Cancer Control, 10% time
and effort Source: NIH/NCI Grant Number: 5 P30 CA16059-20 $586,494 Period of
Support: 6/01/02 - 06/01/07
9.32.111999-3 Principal Investigator. AA randomized clinical trial to evaluate the effectiveness,
cost-effectiveness, and impact on quality of life of implantable narcotic delivery systems
vs. best standardized pain control.” Medtronic, Inc. Minneapolis, MN. Medtronics, Inc.
Minneapolis, MN. ~20% salary and time.
9.32.121999 Principal Investigator, with Dr. Roger Winn, M.D. Anderson Cancer Center,
Houston, Texas. Managed Care Organization Survey, for American Society of Clinical
Oncology. $6977.
9.32.131999 - Hunton Foundation, Richmond, Virginia. $7,000. Education Center for hospice.
9.32.141998-9 Principal Investigator, with Bruce E. Hillner. Assessing the quality of cancer care
in the United States.” Report to the Institute of Medicine and National Cancer Advisory
Board. 25% effort. (Continued consultations)
9.32.151998 Principal Investigator. Randomized clinical trial of implantable narcotic delivery
systems”. Medtronics, Inc. Minneapolis, MN. $20,000. Design of clinical trial.
9.32.161998-1 Principal Investigator. Creation of a Palliative Care Unit to Serve the Medically
Under-served”. Jessie Ball DuPont Fund, Jacksonville, Florida, $287,000/3 years.
9.32.171998-01 Consultant, Economic evaluation of CALGB 9343, K. A. Schulman, MD, PI,
Georgetown University.
9.32.181996-8 Principal Investigator: CALGB 9411, Economic Evaluation of filgrastim (G-CSF)
versus placebo during remission, induction, and consolidation for Adult Lymphoblastic
Leukemia. Contract under negotiation; 10% effort and salary; $108,000. Unrestricted
research grant from CALGB Foundation.
9.32.191997- Consultant, R-25, PI-Peter Raich, MD, AMC Cancer Center, Denver, CO. The
impact of easy to read consent statements on clinical trials”. Eastern Cooperative
Oncology Group, North Central Cancer Treatment Group. 2-4 days/year.
9.32.201996-7 Consultant. PI-Ian Tannock, MD PhD, Ontario Cancer Institute. Economic
analysis of NOV.22 (Phase 3 trial of mitoxantrone plus low dose prednisone versus low
dose prednisone for symptomatic hormone-resistant prostate cancer. $1,000/year.
9.32.211996-7 Consultant.PI-Bruce E. Hillner, MD. Pharmacoeconomic analysis of ECOG
adjuvant interferon melanoma trial. $5,000/year.
9.32.221995-8 Principal Investigator. Open Society, New York. Faculty Scholar, Death in
America Project. 60% effort and salary. Begins July 1, 1995.
9.32.231995-8 Principal Investigator/Mentor. Fellowship in Supportive Care and
Pharmacoeconomics. SmithKlineBeacham unrestricted grant. $54,000/year. 0% support.
9.32.241995-6 Co-Investigator. Cancer and Leukemia Group B 9570. Project to establish
standard method for incorporating economic evaluation within cancer clinical trials. 0%
support.
9.32.251995-8 Co-Principal Investigator. “Effect of case management alternatives on the
satisfaction, quality of life, and cost of care for metastatic nonsmall cell lung cancer
patients.” Williamson Institute for Health Economics, VCU-MCV, Richmond, VA. 10%
salary and support, begins July 1, 1995.
9.32.261994-5 Principal Investigator: "Economic evaluation of GCSF92106: Randomized
clinical trial of filgrastim mobilizes peripheral blood progenitor cell transplantation in
comparison with autologous bone marrow transplantation in patients with Hodgkins
disease and non-Hodgkins lymphoma." $107,000 total; 20% effort and salary.
Unrestricted research contract with AMGEN, Thousand Oaks, CA.
9.32.271993-8 Co-principal investigator, with Dr. Peter Raich. RFP No. CO-33004-63. West
Virginia, Virginia, and Ohio Cancer Information Service, Office of Cancer
Communications, NCI. Massey Cancer Center Subcontract $464,259/5 years. Effective
6/30/93. 5% effort, salary support not included per contract stipulation.
9.32.281993-5 Co-Principal Investigator. "Economic Analysis of Chemotherapy for Non-Small
cell Lung Cancer." Burroughs Wellcome Epidemiology, Surveillance, and
Pharmacoeconomics Section, Research Triangle Park, N. C. 20% effort and salary;
$85,000 total.
9.32.291993-4 Co-Principal Investigator. "Economic Analysis of Rural Cancer Outreach
Programs" Jessie Ball duPont Fund, Jacksonville, Florida. $50,000/1 year.
9.32.301992-5 Career Development Award: "Building models for rational and equitable
distribution of cancer care resources: the use of decision analysis to evaluate efficacy and
cost-effectiveness of therapy." American Cancer Society. Funded 7/1/92. 25% effort,
25% salary; $90,000 total/3 years.
9.32.311991-3 Co-Investigator. "Evaluation of Practice Variations and Costs for Cancer", with
Sheldon Retchin, MD, MSPH. Agency for Health Care Policy and Research. 10% effort,
10% salary.
9.32.321990-2 Principal investigator. "Community Home Health Care for Cancer Patients:
Meeting the Needs of Cancer Patients and their Families in Underserved Areas". Jessie
Ball duPont Religious, Charitable, and Educational Trust Fund. $170,000/3 years.
9.32.331991-3 Principal Investigator. A Pilot Study of Cancer Treatment Combining Histamine
and Histamine2 Receptor Antagonists. Supported by Glaxo Pharmaceuticals, Research
Triangle Park, N.C. $62,300/year.
9.33
Grant Support, pending
9.34
9.35
Invited Seminars (1993-present)
“Breast cancer palliative oncology” School of Breast Oncology, Emory University, Nove
9-11, 2007.
“Integrating palliative care into usual medical care” Stamford Hospital/Columbia School
of Medicine Grand Rounds, November 16, 2007
“Can we afford the future: cost considerations in oncology” University of Vermont
Keynote Speaker, ASCO Update, June 19, 2007
“Preventing oncologist burnout” ASCO Annual meeting Education Session, June 6 and 7,
2007
Special Erythropoesis Stimulating Agents Consensus Panel Member, ASCO Meeting,
June 6, 2007
“Palliative Medicine in everyday practice” EVMS/Sentara Special Lecture series, May 34, 2007
ASCO Annual Prostate Cancer Meeting Special Lecture: “Can we afford our progress?”
February 24, 2007
Co-Chair, Supportive Care Congress, NYC February 23-5, 2007. Lectures: “update in
advanced pain management.” And “Defragmenting the system: ways to improve health
care by coordination”
MacMillan Fund UK Plenary Lecturer: NCRI Annual Conference, Birmingham, UK
October 7, 2006.
Chair, ASCO Annual Meeting, Clinical Problems in Oncology Session “Getting savvy
with opioids to manage cancer pain: routes, rotations, interventions.” June 2006
University of Kentucky Norton Health System, July 2006: Starting Palliative Care
Programs; Interventional Pain Management
ASCO People Living with Cancer “ask the expert” series. June 2006.
ASCO Special education session “Getting savvy with opioids”, June 5-6, 2006
Dartmouth-Hitchcock Norris Cotton Cancer Center Tranforming Cancer Care: Patients at
the Center of Science and Service, New Hampshire, May 25, 2006
City of Hope “Barriers” Keynote Speaker, “Practical approach to managing pain and
fatigue”, Duarte, CA April 13, 2006
Mercy Medical Center, Miami. “Creating palliative care within medicine” February 2006
City of Hope First Annual Mark Schaffner MD Memorial Lecture, November 1, 2005.
ASCO “meet the professor” session, 2005
Virginia Association of Hospices Keynote speaker, April 7, 2005
9.36
9.37
9.38
9.39
9.40
9.41
9.42
9.43
9.44
9.44.1
9.44.2
9.44.3
9.44.4
9.44.5
9.44.6
9.44.7
9.44.8
9.44.9
9.44.10
9.44.11
9.44.12
9.44.13
9.44.14
9.44.15
9.44.16
9.44.17
9.44.18
9.44.19
9.44.20
9.44.21
9.44.22
9.44.23
9.44.24
9.44.25
9.44.26
9.44.27
9.44.28
9.44.29
9.44.30
9.44.31
9.44.32
Society of Behavioral Medicine workshop leader, March 2005, Boston.
American Academy of Hospice and Palliative Medicine keynote speaker, March
2003, Atlanta.
National Supportive Care Congress, “New methods of pain control” February 25,
2005, San Francisco
RAM Shelton Horsely Memorial Lecture, February 2005, Richmond.
Hospice of Michigan/Wayne State University School of Medicine 2nd Annual
Conference. “Cost effective inpatient palliative care” and “New developments in pain
management”. October 8-9, 2004.
ASCO Meet the Professor Sessions, June 2004: “Clinical trials and cost
effectiveness”, New Orleans.
Emory University Winship Cancer Center Keynote Address, June 2004:
“Improving quality of life in supportive care and palliative care patients”
MASCC International Meeting, June 2004: Centers of excellence in palliative and
supportive care. Miami, FL.
Baystate Medical Center Log Cabin Retreat, Northampton, MA, April 2004.
Palliative Care.
DELEtECC National Meeting: “Improving care in palliative care”, City of Hope
National Medical Center, Pasadena, CA, April 2004.
Grand Rounds: Roswell Park Cancer Institute, January 2004.
U. Michigan Cancer Center Grand Rounds, September 2003 “Treatment of
refractory pain”
Karmonos Cancer Center Grand Rounds, September 2003 “Treatment of
refractory pain”
U. Wisconsin Cancer Center Grand Rounds, June 4, 2003 “Treatment of
refractory pain”
NCI Clinical Center Grand Rounds, “Randomized clinical trial results from the
Cancer Pain Trial”, May 21, 2003
Olson Lecture, Bassett Health Care, Cooperstown NY, April 16, 2003.
“Care of the Difficult Patient – whatever that means” Disseminating End of Life
Care to Cancer Centers, City of Hope, Pasedena, CA April 5, 2003.
“The relationship between volume and quality” Society of Surgical Oncology
keynote speaker, March 6, 2003.
“Implantable drug delivery systems for refractory cancer pain”. Association of
Northern California Oncologists, March 5, 2003
“The medical oncologist perspective on refractory cancer pain”. Karmonas Cancer
Center, February 6, 2003
“The medical oncologist perspective on refractory cancer pain”. U Pitt Medical
Center, February 5, 2003
“Clinical trials in advanced cancer pain management” M.D. Anderson Cancer
Center, January 7, 2003
“Implantable drug delivery systems for refractory cancer pain”. Duke University
Medical Center/Cancer Center Anesthesia Grand Rounds, December 4, 2002
“Implantable drug delivery systems for refractory cancer pain”. Memorial Sloan
Kettering Cancer Center, November 2002; Pain and Palliative Care Grand Rounds
9.44.34
Multinational Association for Supportive Care in Cancer (MASCC), “Intrathecal
opioids: review of the evidence” Boston, MA June 26, 2002.
9.44.35
American Alliance of Cancer Pain Initiatives Keynote Speaker: “Cancer pain
management in the new economy” June 14, 2002, Richmond, VA.
9.44.36
ASCO Industry Sponsored Symposium, Chair. “Advances in Pain Management”
May 17, 2002
9.44.37
ASCO Education Session, Annual meeting, May 18, 2002: Follow up care of the
patient with breast and lung cancer.
9.44.38VCU-MCV International Cancer Rehabilitation Conference, Richmond, VA October 20,
2001 “Care of the Difficult Patient”
9.44.39Virginia Commonwealth University Mini-Med School, Richmond, VA “Cancer Pain”
9.44.40Association of Cancer Pain Initiatives Keynote Speaker, June 2001; Madison, WI.
9.44.41American Society of Clinical Oncology: Program Chairman, Symposium on Supportive
Care and Symptom Control. May 11, 2001
9.44.42American Society of Clinical Oncology: Using quality to survive Managed Care. Care.
May 11, 2001
9.44.43Medical Group Management Association: Quality assessment in clinical practice. San
Antonio, April 2001.
9.44.44Iceland Cancer Hospital: Rekjavik, “Improving cancer care”, March 2001
9.44.45American Society of Clinical Oncology: Symposium on Practice Management. AHow to
maximize patient services” May 11, 2001
9.44.46“Technology at end of life” The end of our lives - guiding the research agenda. NIHNINR, Bethesda, MD. November 14, 2000.
9.44.47“Outcomes research” Swiss Society for Clinical Research, Lucerne, Switzerland, June 22,
2000
9.44.48American Society of Clinical Oncology: Program Chairman, Symposium on Supportive
Care. May 19, 2000
9.44.49American Society of Clinical Oncology: Program Chairman, Symposium on Supportive
Care. “Improving Communications with Written treatment plans.” May 19, 2000
9.44.50American Society of Clinical Oncology “Meet the Professor” session on Outcomes
Research, May 1999
9.44.51American Society of Clinical Oncology Education Plenary Session, “Economic and
clinical consequences of CSF Use” May 1999
9.44.52University of Kentucky at Lexington, Effectiveness and cost-effectiveness of high dose
chemotherapy: practice, evidence, and politics. April 17, 1999.
9.44.53Hematology/Oncology Grand Rounds, Massachusetts General Hospital, February
19,1999, Boston MA.
9.44.54Medical Grand Rounds, (Improving Quality in Medical Care); Geriatric Grand Rounds,
(Supportive Care); combined geriatric and oncology fellows conference (advanced
supportive care and chemotherapy), Mt. Sinai School of Medicine, New York, January 5,
1999
9.44.33
9.44.55Oncology Grand Rounds, McGill University Royal Victoria Hospital ‘Can we improve
the quality of cancer care?” November 4, 1998; also, Oncology Research Conference at
McGill “Better care, less cost, satisfied patients”; also, Grand Rounds, Montreal General
Hospital “Putting health service to work in palliative care: ways to improve care and save
money” November 5, 1998
9.44.56“Economics of cancer treatment and care”, National Cancer Survivors Network Meeting:
Atlantic City, N.J., October 8, 1998
9.44.57“Breast cancer follow up strategies”, MCV-VCU Cancer Conference, Richmond VA
October 10, 1998
9.44.58“Improving doctor and patient communication”, Virginia Department of Health Annual
Breast cancer Conference, October 5, 1998
9.44.59“Clinical and economic aspects of hematopoetic growth factor use”, Princess Margaret
Hospital/ Ontario Cancer Research and Treatment Foundation, September 26, 1998.
9.44.60“Clinical and economic aspects of growth factor use”, Atlanta, GA, September 18, 1998.
9.44.61Visiting Professor, McGill University and University of Montreal, November 1998
9.44.62“The usefulness of Utility” 1st Annual NIH Research in Palliative Care Conference,
Bethesda MD May 7-9, 1998
9.44.63“The ethics of cost constraint in oncology” Mont Marie Ethics Symposium, Holyoke, MA
April 26-27, 1998
9.44.64“Lung cancer” and “Update in Hematology” National Cancer Information Exchange
(CIS) Amelia Island, Florida, February 13-15, 1998
9.44.65“Cost savings and quality improvement in oncology” Cancer Center/Medicine Grand
Rounds, Washington Hospital Center, Washington, D.C. January 16, 1998
9.44.66“Palliative Care” Columbia University College of Physicians and Surgeons Harlem
Hospital Medical Grand Rounds, New York, New York, January 7, 1998
9.44.67“Economic analysis of hematopoietic growth factors” European Organization for
Research and Treatment of Cancer, Brussels, Belgium, November 17, 1997
9.44.68“Research in quality of life and economics for palliative care” Japanese Intractable
Disease Society Tokyo, Japan, October 29-30, 1997.
9.44.69“Ethics in health care rationing” Australian Society for Chemotherapy, Sydney, June 30,
1997.
9.44.70“End of Life Management of the cancer patient: emerging problems for the oncologist”
Plenary Session, American Society of Clinical Oncology, Denver CO, May 18, 1997
9.44.71“Economic analysis of end of life care” Education Session, American Society of Clinical
Oncology, Denver CO, May 18 and 19, 1997
9.44.72“Determining prognosis in the incurable patient: how to choose between aggressive,
palliative and hospice care” 2nd Annual Cancer Information Exchange for Primary Care
Providers, Amelia Island, Florida, February 14, 1996
9.44.73“Surveillance testing in curatively treated cancer survivors” American Society of Clinical
Oncology Fall Education Meeting, November 8, 1996, Phoenix, AR.
9.44.74“Principles of Health Care Economics”. Hamilton Regional Cancer Center, McMaster
University, Economics of Health Care in Oncology Symposium, October 7-8, 1996.
9.44.75“Quality of life yardsticks: are they useful?” and ACan the health care system afford the
knowledge we are gaining?” Eighth International Symposium on Supportive Care in
Cancer, Toronto, June 20-22, 1996
9.44.76“Crabs on the Medical Commons: comparing cost-effectiveness of cancer, AIDS, and
cardiology care” Medical Grand Rounds, Ohio State University, Columbus Ohio June 6,
1996.
9.44.77“Evaluating health care plans and providers: use of disease-specific report cards based on
Blue Cross/Blue Shield data” James Cancer Center Grand Round, Ohio State University,
Columbus Ohio, June 6, 1996.
9.44.78“Clinical outcomes and costs of cancer treatment: can we afford the advances we are
making?” American Society of Clinical Oncology Educational Meeting, Philadelphia,
May 18, 1996
9.44.79“Cost-effectiveness of cancer care”. The Cancer Foundation Celebration 1996, Hogsby,
Sweden, March 22, 1996.
9.44.80“Cost of high dose chemotherapy and stem cell replacement: provider, patient, and
insurer perspectives” Workshop leader, Blood Cell and Bone Marrow Transplant
Symposium, Keystone, CO, January 15, 1996.
9.44.81“Cost control in cancer”. Medical Grand Rounds, Winthrop University Hospital, SUNY,
Mineola, NY, December 13, 1995
9.44.82“Pain control in Extremes of Age: children and old adults” Symposium on Pain
Management: Attitudes, Obstacles, and Issues. Senate Joint Subcommittee, Richmond,
VA December 6, 1995
9.44.83“Cost-effective of breast cancer treatments - compared to alternative uses of the same
dollars” Ontario Cancer Institute, Toronto, Ontario; Hamilton Regional Cancer Treatment
Center, Hamilton; London Regional Cancer Treatment Center, London. October 3-5,
1995.
9.44.84“Alternative Methods to Assess Outcomes in High Dose Chemotherapy” American
Society for Blood and Marrow Transplantation, Milwaukee Wisconsin July 27, 1995
9.44.85“Pharmacoeconomics and High Tech High Cost Care: Practice Guidelines in U.S. and
Canada.” Quebec Society of Hematology and Oncology, Val Morin, Province Quebec,
May 31, 1995
9.44.86"Strategic Alliances of Cancer Care Providers: One Solution to Increasing Access and
Lowering Costs of Cancer Treatment." W.H.O. Conference on Palliative Care, Ulm,
Germany, March 13-15, 1995
9.44.87"Studies of Economic Outcomes of Cancer Treatment", 1995 Quality of Life Symposium:
Quality of Life and Economic Outcomes in Cancer Care: a New Focus for Healthcare
Providers, Payers, and Policymakers. Long Beach, CA March 4-5, 1995
9.44.88"Cost effectiveness of bone marrow transplantation: American Society for Blood and
Marrow Transplantation, Keystone, Colorado, January 26, 1995
9.44.89"Meta-analysis Techniques/Outcomes Research" National Autologous Bone Marrow
Transplant Registry Annual Meeting, Keystone, CO, January 23, 1995
9.44.90"Evaluating New Technologies: the Case of Autologous Bone Marrow Transplantation
for Breast Cancer" National Blue Cross Blue Shield Directors Meeting, Chicago, June 27,
1994
9.44.91"Oncology Care Delivery in the Reformed Health Care System" Bios Communications,
New York, June 24-25, 1994
9.44.92"Cost Effectiveness of Palliative Care for Cancer", German Cancer Conference, March
11, 1994, Hamburg, Germany.
9.44.93"Cost Effectiveness of High Dose Chemotherapy for Breast Cancer" May 1994;
American Society of Clinical Oncology Educational Session. With Drs. Karen Antman
and Robert Livingstone.
9.44.94"Effectiveness and cost effectiveness of adjuvant chemotherapy for breast cancer." Tottori
University School of Medicine, Yonago Japan, November 22, 1993
9.45 Other
9.45.1 Patents
9.45.2 Co-patentee. "Treatment and prevention of oral mucositis with growth factors". Triton
Biosciences, Alameda, CA. Patent 5102870, April 7, 1992;
9.45.3 European Patent Office No: 90903469.6-, filed October 30, 1991; the Hague.
10
10.1
10.1.1
10.1.2
10.1.3
10.1.4
10.1.5
10.1.6
10.1.7
10.1.8
10.1.9
10.1.10
10.1.11
Major Committees
University/Hospital
Chair, Oncology Services Committee - 1999Chair, MCVH Oncology Pharmacy and Therapeutics Committee
Promotion and Tenure Committee, Dr. Richard Seither, 1998-99
Promotion and Tenure Committee, Dr. Brian Kavanagh, 1998-99
MCVH Pharmacy and Therapeutics Committee
VCU-MCV Curriculum Revision Committee
VCU-MCV M-II Hematology Curriculum Committee
1997-98 MCV-VCU Endocrinology Chair Search Committee
1996-8 MCVH Pharmacy Chair Search Committee
MCVH Pharmacy Quality Control Standards for Anti-neoplastic Drugs Committee
VCU-MCVH Patient Education Council
10.2
Professional
10.2.1 National Study Section: 1996-01 American Cancer Society, Atlanta GA. Psychosocial,
Behavioral, and Policy Research.
10.2.2
10.2.2.1
10.2.2.2
10.2.2.3
10.2.2.4
10.2.2.5
10.2.2.6
Boards
Editorial Boards (all until present unless noted)
1999 - Editorial Board, Journal of Palliative Medicine
1998- Editorial Advisory Board, Journal of Clinical Oncology, AThe Art of
Oncology: When the Tumor is Not the Target”
1999 - Editorial Board, Evidence-based Oncology
1998- Medical Advisory Board, InTouch, The good health guide to cancer
prevention and treatment, PRR, Inc.
1997- Editorial Board, Journal of Palliative Medicine
10.2.2.7
10.2.2.8
10.2.2.9
10.2.2.10
10.2.2.11
10.2.2.12
10.2.2.13
10.2.2.14
10.2.2.15
10.2.2.16
10.2.2.17
10.2.2.18
10.2.2.19
10.2.2.20
10.2.2.21
10.2.2.22
10.2.2.23
10.2.2.24
10.2.2.25
1994-7 Editorial Board, Oncology
1995- Editorial Board: Journal of Clinical Oncology
1992- Special Features Editor, Clinical Oncology Alert
1992- Editorial Advisory Board, Oncology News International
1998- Commentator, Evidence-Based Medicine
1996- Reviewer, Psychosomatic Medicine
1996- Reviewer, Annals of Cancer Control Research
1996- Reviewer, PharmacoEconomics
1994- Reviewer, Health Canada, Ontario, Canada
1994- Reviewer, JAMA
1994- Reviewer, Medical Research Council, London, Great Britain
1993- Reviewer, New England Journal of Medicine
1993- Reviewer, Cancer Investigation
1993-Reviewer, Journal of the National Cancer Institute
1993-Reviewer, Radiation Oncology Investigations
1993-Reviewer, AHFS Drug Information
1992-Reviewer, Cancer
1991-Reviewer, Journal of Clinical Oncology
1988-Reviewer, Cancer Research
10.2.3
10.2.3.1
10.2.3.2
Councils
NIH-NCI Lung Cancer Progress Group, 2001
Institute of Medicine/National Academy of Sciences. Enhancing Data Systems to
Improve the Quality of Cancer Care. October 4-6, 1999.
National Marrow Donor Program (NMDP) Registry Size Analysis Review Panel
1998-2002
NIH Conference on Research in Palliative Care Planning Committee, 1999 - 00
The March for Cancer, Basic Science and Research Planning Group, Washington,
D.C., October 1998 (report issued November 1998)
NIH Conference on Research in Palliative Care Planning Committee, 1998-2000
Planning Group, Institute for Healthcare Improvement, Breakthrough Series on
Improving Care
Member, ASCO Panel on Cancer Care at the End of Life, Lowell E. Schipper, MD, Chair
Peer reviewer, Virginia Health Quality Center, Richmond VA, 1996
Regional Quality Council Specialty Advisory Panel, CIGNA, 1996
Advisory Panel, Center for Health Policy Studies, ACancer Information for Lowliteracy Women”, Columbia MD, 1996
Steering Committee, American Society of Clinical Oncology Technology
Assessment of High Dose Chemotherapy with Stem Cell Support, 1994
American Society of Clinical Oncology Technology Assessment Committee
Organizing Committee, American Society of Clinical Oncology Outcomes Research
Work Group
Agency for Health Care Policy and Research (AHCPR) Review Group on
Guidelines for Cancer Pain Management, 1992
10.2.3.3
10.2.3.4
10.2.3.5
10.2.3.6
10.2.3.7
10.2.3.8
10.2.3.9
10.2.3.10
10.2.3.11
10.2.3.12
10.2.3.13
10.2.3.14
10.2.3.15
10.2.3.16
11
11.1
11.2
11.2.1
11.2.2
11.2.3
11.2.4
11.2.5
11.3
11.3.1
11.3.2
11.3.3
11.3.4
American Society for Clinical Oncology Working Group on Technology
Assessment; Ad Hoc Committee for Development of Guidelines for the Use of
Hematopoietic Growth Factors, 1992
Other significant scholoarly, research, or administrative experience
Graduate students trained
Post-doctoral trainees
Dr. David Bloomfield, Oncology Fellow, Princess Margaret Hospital, Toronto,
Ontario Canade, thesis co-advisor/consultant with Ian Tannock, published in Journal
of Clinical Oncology 1998
Dr. Simona Milanese, supervised her analysis of a completed randomized clinical
trial, published in Eur J Cancer
Dr. David Robinson, supervised his design of a Markov Model to evaluate
effectiveness and cost effectiveness of interferon-alpha vs bone marrow
transplantation for chronic myelogenous leukemia. Not published.
Post doctoral fellowship: Robin Matsuyama PhD, 2005-6
Pre doctoral student: Kristie Stover, 2004-5. PhD December 2005.
Major Teaching Assignments (all continuous unless specified)
1996 - MII Hematology Course: Ethics and end of life care; medical care of the ding
patient; Plasma cell disorders and leukemias
1995 - Health Administration Seminar: Health Systems Analysis and Evaluation
Methods; Longtitudinal study designs; cost analysis
1993 - Health Administration 763 (doctoral level course): cost-effectiveness
analysis; policy analysis based on outcomes
1991 - 6 M-IV Elective #8892. "Cancer Care in Rural Virginia."
12
Bibliography
12.1
Papers Published (*primary or corresponding author)
12.1.1 *Smith T, Viverette JF, Adelman BA. The Use of Antithrombotic Therapy in the
Elderly. Geriatric Clinics of North America 1: 877-897, 1985.
12.1.2 *Smith T: Fatty Replacement of Lymph Nodes Mimicking Lymphoma Relapse. Cancer
68(12): 2686-2688, 1986.
12.1.3 *Smith T: Acute Tumor Lysis Syndrome Following Platelet Transfusion. Virginia
Medical 113:100-101, 1986.
12.1.4 *Smith T, Clark JW, Popp MB: Regression of Tumor Nodules in a Patient Treated with
Ranitidine. Archives of Internal Medicine 147(10): 1815-1816, 1987.
12.1.5 *Smith T: Tumor Lysis Syndrome after Steroid Therapy for Anaphylaxis. Southern
Medical Journal 81(3):415-416, 1988.
12.1.6 *Smith T: H2 Receptor Antagonists and Cancer Immunotherapy. Comprehensive
Therapy 16:8-13, 1990.
12.1.7 *Smith T, Grossberg HG: Successful Use of Granulocyte-Macrophage Colony
Stimulating Factor in Patients with Acute Lymphocytic Leukemia. American Journal of
Medicine 1990;89:384-386.
12.1.8 *Smith T. Editorial: Author! Author! JAMA 263:3193, 1990.
12.1.9 *Smith T, Kaplowitz LG: Treatment of Kaposi's Sarcoma in AIDS Patients with
Cimetidine. JNCI 83:139-141, 1991.
12.1.10 *Smith TJ, Desch CE. Neutropenia-wise and pound-foolish: care of the massively obese
chemotherapy patient. Southern Medical Journal 84:883-885, 1991.
12.1.11 Hillner BE, Smith T. Efficacy and cost-effectiveness of adjuvant chemotherapy in
women with node-negative breast cancer. A decision analysis model. N Engl J Med
324:160-168, 1991.
12.1.12 Hillner BE, Smith TJ. A model of chemotherapy in node-negative breast cancer. JNCI
Monographs 11:143-149, 1992.
12.1.13 *Smith T, Desch C, Simonson C, Kane N. Teaching subspecialty medicine in a rural
hospital. J Cancer Education 6:1-6, 1991.
12.1.14 *Smith TJ, Desch CE, Kaplowitz LG. Pulmonary Disease in the AIDS Patients with
Kaposi's sarcoma. Infections in Medicine 9(2):10-16, 1992.
12.1.15 Desch CE, Lasala MR, Smith TJ, Hillner BE. The Optimal Timing of Autologous Bone
Marrow Transplantation in Hodgkin's Disease Patients Following a Chemotherapy
Relapse. J Clin Oncol 10:200-209, 1992.
12.1.16 Smith TJ, Brown PA. The Cancer Information Service: What it can do for you. Indian
Health Service Provider, 16(10):156-157, 1991.
12.1.17 Desch CE, Smith TJ, Briendel CA, Simonson CJ, Kane N. Cancer Treatment in Rural
Areas. Hospital and Health Services Administration 37:449-463, 1992.
12.1.18 Hillner BE, Smith TJ, Desch CE. Efficacy and Cost-Effectiveness of Autologous Bone
Marrow Transplantation in Metastatic Breast Cancer -- Estimates using decision analysis
while awaiting clinical trial results. JAMA 267:2055-2062, 1992.
12.1.19 Brown PA, Ames N, Mettger W, Smith TJ, Gramarossa G, Friedell GH, McDonald SS.
Closing the Comprehension Gap: The link between cancer and illiteracy. JNCI
Monographs 14:147-156, 1993.
12.1.20 Hillner BE, Smith TJ. Should women with node-negative breast cancer receive adjuvant
chemotherapy? Insights from a decision analysis model. Breast Cancer Research and
Treatment 23:17-27, 1992.
12.1.21 Desch CE, Hillner BE, Smith TJ, Retchin SR. Should the elderly receive chemotherapy
for node-negative breast cancer? A Cost -Effectiveness Analysis Examining Total and
Active Life-Expectancy Outcomes. J Clin Oncol 11:777-782, 1993.
12.1.22 *Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early
breast cancer in premenopausal women. J Clin Oncol 11:771-776, 1993.
12.1.23 Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness analysis of adjuvant
therapies in early breast cancer using a decision analysis model. Breast Cancer Research
and Treatment 25:97-105, 1993.
12.1.24 *Smith TJ, Desch CE, Hillner BE. Efficacy and Cost-effectiveness in Oncology:
Rational Allocation of Cancer Care Resources. JNCI 85:1460-71, 1993.
12.1.25 *Smith TJ. Which Hat Do I Wear? Discussing Costs of Breast Cancer Treatment with
Patients. JAMA 270:1657-1659, 1993.
12.1.26 *Smith TJ, Desch CE, Hillner BH. Ways to reduce the cost of oncology care without
compromising the quality. Cancer Investigation 12:257-265, 1994.
12.1.27 Hillner BE, Smith TJ, Desch CE. Principles of cost effectiveness analysis for the
assessment of current and new therapies. J Hematherapy 2:501-506, 1993.
12.1.28 Hillner BE, Smith TJ, Desch CE. Cost-effective use of autologous bone marrow
transplantation: few answers, many questions, and suggestions for future assessments.
Pharmacoeconomics 6:114-126, 1994.
12.1.29 Hampton CL, Mazmanian PE, Smith TJ. Applying telecommunications technology: a
case study of a videoconference to disseminate breast cancer guidelines. Journal of
Continuing Education in the Professions 14:83-89, 1994.
12.1.30 ASCO Ad Hod Colony-stimulating factor Guidelines Expert Panel. American Society of
Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating
Factors: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 12:2471-2508,
1994.
12.1.31 Hillner BE, Smith TJ. Cost effectiveness and other assessments of adjuvant therapies of
early breast cancer. Oncology 1995;9(11S):129-34.
12.1.32 Franzak FJ, Smith TJ, Desch CE. Marketing cancer care to rural residents. Journal of
Public Policy and Marketing 14:76-82, 1995.
12.1.33 Desch CE, Hillner BE, Smith TJ. Economic considerations in the care of lung cancer
patients. Curr Opin Oncol 1996;8:126-32.
12.1.34 *Smith TJ, Hillner BE, Neighbors DN, McSorley PA, Le Chevalier T. Efficacy and cost
effectiveness of chemotherapy for non-small cell lung cancer: results from a clinical trial
comparing vinorelbine, vinorelbine plus cisplatin, and vinorelbine plus cisplatin. J Clin
Oncol 1995;13:2166-73.
12.1.35 *Smith TJ, Penberthy L, Desch CE, Whittemore M, Newschaffer C, Hillner BE,
McClish D, Retchin SM. Differences in initial treatment patterns and outcomes of lung
cancer in the elderly. Lung Cancer 1995;13:235-252.
12.1.36 *Smith TJ, Bodurtha JN. Ethics in Oncology: Balancing interests of the patient,
oncologist, and society. J Clin Oncol 1995;13:2464-70.
12.1.37 Bennett CL*, Smith TJ*,George SL, Hillner BE, Fleishman S, Neill B. Free Riding and
the Prisoner's Dilemma:Problems in funding economic analyses of phase III cancer
clinical trials J Clin Oncol, 1995;13:2457-63.
12.1.38 Smith TJ*. Decision Analysis in Oncology. Oncology, 1995;9S:37-46.
12.1.39 Desch CE, Penberthy LP, Newschaffer CJ, Hillner BE, Whittemore J, McClish D, Smith
TJ, Retchin SM. Factors that determine the treatment for local and regional prostate
cancer. Medical Care 1996;34:152-162.
12.1.40 Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear H. Tradeoffs between
survival and breast preservation for three initial treatments of ductal carcinoma of the
breast. J Clin Oncol 1996;14:70-77.
12.1.41 American Society of Clinical Oncology Outcomes Working Group (core member,
manuscript editor). Outcomes of cancer treatment for technology assessment and cancer
treatment guidelines. J Clin Oncol 1996;14:671-679.
12.1.42 Desch CE, Smith TJ. Defining treatment aims and end-points in older patients with
cancer. Drugs & Aging 1995;6:351-357.
12.1.43 Hillner BE, Smith TJ. Cost-effectiveness analysis of three regimens using vinorelbine
(Navelbine) for non-small cell lung cancer. Seminars in Oncology 1996;23 (S):25-30.
12.1.44 Smith TJ*. Economic analysis of CSFs. Curr Opin Hemat 1996;3:175-179.
12.1.45 Teague KE, Brown JA, Meyer JM, Kahn MJK, Smith TJ, Bodurtha JN. Teaching
efficacy of a medical education module on genetic testing for breast cancer. J Cancer
Educ 1996;11:196-202.
12.1.46 Smith T*. Lessons in Survival. In “Caring for the Dying: Identification and promotion of
physician competency.” American College of Physicians. ACP, Philadelphia, PA, 1997.
12.1.47 Hillner BE, Penberthy L, Desch CE, McDonald MK, Smith TJ, Retchin SM. Variation
in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer
Research and Treatment 1996;40:75-86.
12.1.48 Ozer H, Miller LL, Schiffer CA, Winn RA, Smith TJ* (manuscript editor). American
Society of Clinical Oncology Update of Recommendations for the Use of Hematopoietic
Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol
1996;14:1957-1960.
12.1.49 Hillner BE, McDonald MK, Penberthy L, Desch CE, Smith TJ, Maddox P, Glasheen
WP, Retchin SM. Measuring standards of care for early breast cancer in an insured
population. J Clin Oncol 1997;15:1401-1408.
12.1.50 Winn RJ, Smith TJ. The American Society of Clinical Oncology Guideline Program.
Pharmacy Practice Management Quarterly 1996;16:31-38.
12.1.51 Smith TJ*, Desch CE, Grasso MA, McCue MJ, Buonaito D, Grasso K, Johantgen ME,
Hackney MH, Shaw JE, Simonson CJ. The rural cancer outreach program: clinical and
financial analysis of palliative and curative care for an underserved population. Cancer
Treatment Reviews 1996;22S:97-101.
12.1.52 Hillner BE, Smith TJ. Cost effectiveness and other assessments of adjuvant therapies for
early breast cancer. Oncology 1995;9S:129-134.
12.1.53 Desch CE, Smith TJ. Economic considerations in the care of lung cancer patients.
Current Opinion in Oncology 1996;8:126-132.
12.1.54
Smith TJ*, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts
MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH. Economic.
Analysis of a Randomized Clinical Trial to Compare Filgrastim-Mobilized
Peripheral Blood Progenitor Cell Transplantation and Autologous Bone Marrow
Transplantation
12.1.55
Bennett C, Smith T, Weeks J, Bredt J, Feinglass J, Fettting J, Hillner B, Somerfield
M, Winn R. Use of hematopoietic colony stimulating factors: the American Society
of Clinical Oncology Survey. J Clin Oncol 1996;14:2511-2520.
12.1.56
National Work Group on Literacy and Health (core member). Report of the National
Work Group on Literacy and Health: suggestions for clinical practice and research. J
Family Practice 1998;46:168-176.
12.1.57
Smith TJ. Lessons from living among the dying. Journal of Pastoral Care
1997;51:237-240.
12.1.58
ASCO Tumor Marker Expert Panel (manuscript editor). Clinical practice guidelines
for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;
12.1.59
12.1.60
12.1.61
12.1.62
12.1.63
12.1.64
12.1.65
12.1.66
12.1.67
12.1.68
12.1.69
12.1.70
12.1.71
12.1.72
12.1.73
14:2843-2877.
Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic Analysis
of Adjuvant Interferon-alpha B in High Risk Malignant Melanoma. J Clin Oncol
1997;15:2351-2358.
Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy LT, Maddox P, Retchin
SM. Costs of care associated with non small cell lung cancer in a commercially
insured cohort. Journal of Clinical Oncology 1998;16:1420-1424.
Morrison SE, Meier DE, Cassel CK. [Smith TJ, Discussant, Clinical ProblemSolving] When too much is too little. N Engl J Med 1996;335:1755-60.
Smith TJ*, Hillner BE, Mitchell RB. Editorial. Decision analysis in non-small cell
lung cancer: not back to the drawing modeling board, back to the bedside. J Clin
Oncol 1997;15:870-872.
Breast cancer surveillance expert panel (panel member, manuscript editor).
Recommended breast cancer surveillance guidelines. J Clin Oncol 1997;15:21492156.
Milanese S, Hansen LA, Desch CE, Honeycutt C, Tesfaye F, Smith TJ*. Impact of
histamine and histamine-2 receptor antagonists on quality of life and anti-tumor
response: results of a pilot trial. European J Cancer 1998;33(14):2436-2437.
Smith TJ, Desch CE, Hackney MH, Shaw JE. How long does it take to get a Ado not
resuscitate order”? J Palliat Care 1997;13:5-8.
Update of ASCO clinical practice guidelines for hematopoeitic growth factors, 1997.
(Manuscript editor) Journal of Clinical Oncology, in press.
ASCO Non-small cell lung cancer expert panel. Clinical practice guidelines for the
treatment of unresectable non-small-cell lung cancer. J Clinical Oncology 1997;
15:2996-3018.
*Smith TJ, Somerfield MR. The ASCO experience with evidence-based clinical
practice guidelines. Oncology 1997;11(Suppl 9):1-5.
*Smith TJ, Bear HD. (Editorial) Colorectal cancer follow up: making guidelines
based on the evidence. Gastroenterology 1998;114:211-213.
*Smith TJ, Mitchell RB. (Editorial) The Mather Article Reviewed: Economic and
clinical analysis of lung cancer treatments. Oncology 1998;12:210-216.
*Smith TJ, Swisher K, Ulmer D, Mitchell RB, Colley LJ. A randomized clinical trial
to involve cancer patients in decisions about palliative chemotherapy and radiation
therapy by Apatient indemnification”: reasons for failure of the trial. Submitted.
Bast R, Desch CE, Hayes DF, Kemeny NE, Ravdin P, Somerfield MR, Smith TJ
[manuscript editor]. 1997 Update of recommendations for the use of tumor markers
in breast and colorectal cancer: report of the American Society of Clinical Oncology
Expert Panel. J Clin Oncol 1998; 16:793-5.
Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR,
Ernst S, Moore MJ, Neville A, Tannock IF. Economic evaluation of chemotherapy
with mitoxantrone plus prednisone for symptomatic hormone resistant prostate
cancer, based on a Canadian randomized trial with palliative endpoints. J Clin Oncol
1998, 16:2272 -2279.
12.1.74
12.1.75
12.1.76
12.1.77
12.1.78
12.1.79
12.1.80
12.1.81
12.1.82
12.1.83
12.1.84
12.1.85
12.1.86
12.1.87
12.1.88
12.1.89
Brown ML, Glick HA, Harrell FE, Herndon JE, McCabe MS, Moinpour CM,
Schulman K, Smith TH, Weeks JC, Seils DM. Integrating economic analysis into
cancer clinical trials: the NCI-ASCO Economics Workbook. J Natl Cancer Institute
Monographs 1998;24:1-28.
*Smith TJ, Somerfield MJ, Desch CE, David M. Would oncologists want
chemotherapy if they had non-small cell lung cancer? Results of a 1997 survey.
Oncology 1998;12:360-65.
Desch CE, Grasso M, McCue M, Buonaiuto D, Grasso K, Smith TJ.* A rural cancer
outreach program lowers patient care costs and benefits both the rural hospitals and
sponsoring academic medical center. J Rural Health, 1999;15:157-167.
*Smith TJ, Schnipper LJ. The American Society of Clinical Oncology Program to
Improve End of Life Care. J Palliative Medicine 1998;1:221-230.
Hillner BE, Smith TJ. [Editorial] When does a clinical trial warrant an economic
analysis?. JNCI 1998;90:724-5.
*Smith TJ, Swisher K. [Editorial] Telling cancer patients the truth: why we should,
why we don’t, and why it matters. JAMA 1998;279:1746-1748.
American Society of Clinical Oncology Task Force on End of Life Care. [Panel
member, editor of sections on Economic Barriers, Elements of Quality of Care]
Cancer care during the last phase of life. J Clin Oncol 1998;16:1986-96.
Penberthy L, Retchin SM, McDonald MK, McClish DK, Desch CE, Smith TJ,
Hillner BE, Newschaffer CJ. Predictors of Medicare costs in elderly beneficiaries with
breast, colorectal, lung, or prostate cancer. Health Care Manag Sci 1999;2:149-60.
*Smith TJ. Health service studies in the terminally ill patient. Cancer Treat Res
1998;97:81-97.
Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy LT, Retchin SM. A
comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger
and Medigap Commercially insured cohort. Cancer 1998;83:1930-7.
Hillner BE, Smith TJ (editorial). Hospital volume and patient outcomes in major
cancer surgery: a catalyst for quality assessment and concentration of cancer
services. JAMA 1998;280:1783-4.
Desch CE, Penberthy LT, Hillner BE, McDonald MK, Smith TJ, Pozez AL,
RetchinSM. A sociodemographic and economic comparison of breast reconstruction,
mastectomy, and conservative surgery. Surgery, 1999;125:441-447.
Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization
and outcome in cancer treatment. Journal of Clinical Oncology 2000;18:2327-2340.
Somerfield MR, Stefanek ME, Smith TJ. A systems model for adaptation to somatic
distress among cancer survivors. Psycho-oncology, 1999, 8:334-343.
*Smith TJ, Davidson NE, Schapira DV, Grunfeld E, et al. American Society of
Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance
Guidelines. J Clinical Oncology 1999;17:1080-82.
*Smith TJ, Hillner BE. Clodronate reduced the incidence of bony and visceral
metastases in patients with breast cancer and tumor cells in the bone marrow
Evidence-Based Medicine 1999;4:43.
12.1.90
Smith TJ, Hillner BE. Tamoxifen should be cost-effective in reducing breast cancer
risks in high-risk women. Journal of Clinical Oncology 2000, 18:284-286.
12.1.91
Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of
Hematopoietic Colony Stimulating Factors: Comparison of the 1994 and 1997
American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice
Guidelines. Journal of Clinical Oncology, 1999,17: 1-6.
12.1.92
Arthur DW, Schmidt-Ullrich RK, Friedman RB, Wazer DE, Kachnic LA, Amir C,
Bear HD, Hackney MH, Smith TJ, Lawrence W. Accelerated Superfractionated
Radiotherapy for Inflammatory Breast Carcinoma: Complete Response Predicts
Outcome and Allows for Breast Conservation. Int. J. Radiation Oncology Biol.
Phys., 1999, 44:289-296.
12.1.93
Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. for
the Health Services Research Committee of the American Society of Clinical
Oncology. The association between physician reimbursement in the US and use of
hematopoeitic colony stimulating factors as adjunct therapy for older patients with
acute myeloid leukemia: Results from the 1997 American Society of Clinical
Oncology survey. Annals of Oncology, 1999, 10:1355-1359.
12.1.94
Hillner BE, Weeks JC, Smith TJ, Desch CE. Pamidronate in prevention of bone
complications in metastatic breast cancer: a cost effectiveness analysis. Journal of
Clinical Oncology, 2000, 18:72-79.
12.1.95
Smith TJ. Future strategies needed for palliative care. Seminars in Radiation
Oncology, 2000, 10:254-261.
12.1.96
Smith TJ. Tell it like it is. Journal of Clinical Oncology, 2000, 18:3441-3445.
12.1.97
Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY,
Mennel RG, Smith TJ Somerfield MR. 2000 update of recommendations for the
use of tumor markers in breast and colorectal cancer. Journal of Clinical Oncology,
2001, 19:1865-1878.
12.1.98
Desch CE, Benson AB, Flynn PJ, Krause Loprinzi CL, Minsky BD, Petrelli NJ,
Pfister DG, Smith TJ, Somerfield MR. 2000 Update of ASCO Colorectal Cancer
Surveillance Guidelines. Journal of Clinical Oncology, 2000, 18:3586-3588.
12.1.99 Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA,
Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfeld MR.
(ASCO Special
12.1.100 Smith TJ, Girtman J, Riggins J. Why Academic Divisions of Hematology/Oncology
Are in Trouble and Some Suggestions for Resolution. Journal of Clinical Oncology,
2001, 19:260-264.
12.1.101 *Smith TJ, Hillner BE. Ensuring Quality Cancer Care by the Use of Clinical Practice
Guidelines and Critical Pathways. J Clin Oncol 2001 19: 2886-2897.
12.1.102 Smith TJ, Penberthy L, Hillner BE, Desch CE, Retchin S. Hospice utilization by
Medicare beneficiaries in Virginia. Submitted.
12.1.103 Charles L. Loprinzi, Daniel Hayes, and Tom Smith. Doc, Shouldn’t We Be Getting
Some Tests? J Clin Oncol 2000 18: 2345-2348
12.1.104 Lyckholm LJ, Hackney MH, Smith TJ. Ethics of rural health care. Critical Reviews in Oncology/He
12.1.105 Coyne P, Ramakrishnan V, Smith TJ. Nebulized fentanyl improves patients’
perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain
Symptom Management, 2002 23: 157-60.
12.1.106 Neff P, Lyckholm L, Smith T. Truth or consequences: what to do when the patient
doesn’t want to know. J Clin Oncol 2002;20:3035-3037.
12.1.107 Payne SK, Coyne P, Smith TJ. The health economics of palliative care. Oncology
(Huntingdon) 2002;16:801-808.
12.1.108 Smith TJ, Staats PJ, Pool G, Coyne P, et al. Randomized clinical trial of
comprehensive medical management of refractory cancer pain vs. comprehensive
medical management plus intrathecal implantable drug delivery systems. Journal of
Clinical Oncology 2002; 20: 4040-9
12.1.109 Quillin JM, Boardman CH, Bodurtha J, Smith T. Preventive gynecologic surgery for
BRCA1/2 carriers--information for decision-making. Gynecol Oncol. 2003
Oct;83(1):168-70
12.1.110 Smith T. Adding hospice and palliative care services to the cancer center
menu. J Palliat Med 2003;6:641-644.
12.1.111 Smith TJ, Cassel JB, Coyne PS, Hager MA. A high-volume specialist palliative care
unit and team may reduce in-hospital end-of-life care costs. J Pall Medicine 2003;6:699705.
12.1.112 Smith TJ. Medically appropriate follow up of the patient with lung cancer: an
evidence based approach. Seminars in Oncology, June 2003:30;361-368.
12.1.113 Smith TJ, Coyne P, Staats P. Implantable drug delivery systems: what is the
evidence? Supportive Cancer Therapy 2004:1:1-5.
12.1.114 Smith TJ, Coyne P. How to use implantable intrathecal drug delivery systems for
refractory cancer pain. J Supportive Oncology 2003:1:1-4.
12.1.115 Smith TJ, Hillner BE, Bear HD. Taking action on the volume-quality relationship:
How long can we hide our heads in the colostomy bag? J Natl Cancer Inst 2003;95:6958. (Invited editorial.)
12.1.116 Smith TJ. We can reduce the cost of in-hospital end of life care. Oncology Times
2003;225(11):4-6.
12.1.117 Penberthy L, McClish D, Manning C, Retchin S, Smith TJ. The Added Value of
Claims for Cancer Surveillance: Results of Varying Case Definitions. Med Care. 2005
Jul;43(7):705-12.
12.1.118 French, W., Coyne, P., and Smith, T., "Peer Viewpoint: Management of Dyspnea."
Journal of Supportive Oncology. Vol. 1 No. 1, May/June 2003 pp. 28-29.
12.1.119 Smith TJ, Swainey C, Coyne PJ. Pain Management, including Intrathecal Pumps.
Current Oncology Reports,.Curr Oncol Rep. 2004 Jul;6(4):291-6.
12.1.120 Coyne, P. J., Hansen, L., Laird, J., Buster, P. and Smith, T., "Massive
Hydromorphone Dose Delivered Subcutaneously Instead of Intrathecally : Guidelines for
Prevention and Management of Opioid, Local Anesthetic and Clonidine Overdose."
Journal of Pain and Symptom Management . Vol 28/3 pp 273-276
12.1.121 Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E,
Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL
Jr, Bennett CL, Scher HI; American Society of Clinical Oncology. American Society of
Clinical Oncology Recommendations for the Initial Hormonal Management of
Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer. JCO Jul 15
2004: 2927-2941.
12.1.122 Webb-Wright J, Sacks TE, Smith TJ. The Cherny article reviewed. Oncology 18(12):
18-19, 2004.
12.1.123 Smith T, Coyne PJ, for the Cancer Pain Trial investigators. Implantable drug
delivery systems (IDDS) after failure of comprehensive medical management (CMM)
can palliate symptoms in the most refractory cancer pain patients. J Pall Medicine
8(4):736-42, 2005.
12.1.124 Smith TJ, Coyne PJ, Smith WR, Roberts JD, Smith VS. Use of an Implantable Drug
Delivery System for Refractory Chronic Sickle Cell Pain. Am J Hematology 2005
Feb;78(2):153-4.
12.1.125 Smith TJ, Staats PJ, Pool G, Coyne P, et al. Intrathecal implantable drug delivery
systems give sustained pain control, less side effects, and possibly better survival for six
months: results of a randomized clinical trial vs. comprehensive medical management.
Ann Oncol. 2005 May;16(5):825-33. Epub 2005 Apr 7.
12.1.126 Smith TJ. The American Society of Clinical Oncology Recommended Breast Cancer
Surveillance Guidelines can be done in a routine office visit. J Clin Oncol. 2005 Sep
20;23(27):6807
12.1.127 Smith TJ, Khatcheressian J. Review: chemotherapy and hormonal therapy reduce
recurrence and mortality at 15 years in early breast cancer. ACP J Club. 2005 NovDec;143(3):58.
12.1.128 Khatcheressian J, Cassel JB, Lyckholm L, Coyne P, Hagenmueller A, Smith TJ.
Improving palliative and supportive care in cancer patients. Oncology (Williston Park).
2005 Sep;19(10):1365-76; discussion 1377-8, 1381-2, 1384 passim.
12.1.129 Coyne PJ, Smith T, Laird J, Hansen LA, Drake D. Effectively starting and titrating
intrathecal analgesic therapy in patients with refractory cancer pain. Clin J Oncol Nurs.
2005 Oct;9(5):581-3. Review.
12.1.130 Smith TJ, Swainey C, Coyne PJ. Pain management, including intrathecal pumps.
Curr Pain Headache Rep. 2005 Aug;9(4):243-8. Review.
12.1.131 Khatcheressian JL, Smith TJ. (Ed) Randomized Trial of Long-Term Follow-Up for
Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. J
Clin Oncol. 2006;24:1-3.
12.1.132 Smith TJ, Khatcheressian J. Review: chemotherapy and hormonal therapy reduce
recurrence and mortality at 15 years in early breast cancer. ACP J Club. 2005 NovDec;143(3):58. No abstract available.
12.1.133 Smith T, Khatcheressian J, Lyman G, Ozer H, et al. 2006 ASCO recommendations
for the use of white blood cell growth factors. J Clin Onc 2006;24:1-19.
12.1.134 Matsuyama R, Reddy SN, Smith TJ. Why do patients choose chemotherapy near the
end of life? A review of the perspective of those facing death from cancer. J Clin Oncol.
2006 Jul 20;24(21):3490-6. Review.
12.1.135 Khatcheressian JL, Wolff AC, Smith TJ, GrunfeldE, Muss HB, Vogel VG III,
Halberg F, Somerfield MR, Davidson NE, American Society of Clinical Oncology 2006
Update of the Breast Cancer Follow-up and Management Guideline in the Adjuvant
Setting. J Clin Oncol. 2006 Nov 1;24(31):5091-7. Epub 2006 Oct 10.
12.1.136 White K, Stover KG, Cassel JB, Smith TJ. Nonclinical outcome of hospital based
palliative care. Journal of Healthcare Management 2006;51:253-265.
12.1.137 Khatcheressian J, Smith T. Practice changing implications today, compelling data for
tomorrow. Palliative and Supportive Care (eds). Oncology 2006; 20: 43-8.
12.1.138 Kracen AC, Matsuyama R, Reddy S, & Smith T. (2006). Non-small cell lung cancer:
A patient’s end of life decision to pursue chemotherapy. The American Journal of
Hematology/Oncology, 5, 687-690.
12.1.139 Sterling RK, Lyons CD, Stravitz RT, Luketic VA, Sanyal AJ, Carr ME, Smith TJ,
Hackney MH, Contos MJ, Mills SA, Kuhn JG, Nolte ME, Shiffman ML. Percutaneous
liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure
and impact of human immunodeficiency virus coinfection on the spectrum of liver
disease. Haemophilia. 2007 Mar;13(2):164-71.
12.1.140 Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast
cancer trastuzumab? J Clin Oncol. 2007 Feb 20;25(6):611-3.
12.1.141 Kelso CM, Lyckholm LJ, Coyne PJ, Smith TJ. Palliative care consultation in the
process of organ donation after cardiac death. J Palliat Med. 2007 Feb;10(1):118-26.
Review.
12.1.142 Lingerfelt BM, Swainey CW, Smith TJ, Coyne PJ. Nebulized lidocaine for
intractable cough near the end of life. J Support Oncol. 2007 Jul-Aug;5(7):301-2
12.1.143 Youssef JA, Lyckholm LJ, Smith TJ, Shickle L, Parker GG, Matsuyama RK. A
comparison of hematology/oncology clinic attendance between insured and underinsured
patients at an urban academic hospital: Identifying barriers and ways to overcome them.
Supp Oncol. 2006;4:435-Abstract PA-16. Available from: www.supportiveoncology.net.
Accessed 02/15/07.
12.1.144 Matsuyama, RK, Grange, C, Lyckholm LJ, Utsey SO, Smith TJ. Cultural Perceptions
in Cancer Care among African-American and Caucasian Patients. Jrnl Ntl Med Assoc .
2007; 99(10): 1113-1119
12.1.145 Grange C, Matsuyama RK, Ingram K, Lyckholm LJ, Smith TJ. Identifying
supportive and unsupportive responses of others: Perspectives of African-American and
caucasian cancer patients. J Psychosoc Oncol. in press.
12.1.146 Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS,
Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd,
Bennett CL, Scher HI; American Society of Clinical Oncology. Initial hormonal
management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer:
2006 update of an American Society of Clinical Oncology practice guideline. J Clin
Oncol. 2007 Apr 20;25(12):1596-605. Epub 2007 Apr 2. Review.
12.2
Abstracts (no longer put in c.v.)
12.3
Books/Chapters
12.3.1 *Smith T, Hansen LA: "Antineoplastic Therapy", in Ornato JP and Gonzalez ER. (eds):
12.3.2
12.3.3
12.3.4
12.3.5
12.3.6
12.3.7
12.3.8
12.3.9
12.3.10
12.3.11
12.3.12
12.3.13
12.3.14
12.3.15
12.3.16
12.3.17
Handbook of Pharmacotherapeutics in Emergency Medicine, Churchill Livingstone,
New York, 1990
*Smith TJ, Desch CE, Hillner BE. "Analysis of Economic Issues" in High Dose Cancer
Therapy: Pharmacology, Hemopoietins, and Stem Cells, (eds) Antman K, Armitage JO.
Williams and Wilkins, Baltimore MD. 1992.
Desch CE, Smith TJ*. Breast Cancer Diagnosis and Treatment Update: 1993 and
Beyond. American Health Consultants, Atlanta, Georgia, 1993.
Bennett CL, Hillner BE, Smith TJ*. "Economic Analysis of Cancer Care" in Abeloff
MA, Armitage JO, Lichter AS, Neiderhuber JE (eds) Clinical Oncology Churchill
Livingstone, 1994.
*Smith TJ, Hillner BE, Desch CE. High dose chemotherapy for breast cancer: efficacy,
cost, and cost-effectiveness. in American Society of Clinical Oncology Educational
Book, Chicago, Illinois. p 86-91.
Hillner BE, Smith TJ. Methods of developing clinical practice guidelines. in American
Society of Clinical Oncology Educational Book, Chicago, Illinois. p 261-265.
Bennett CL, Smith TJ, Gulati SC, Armitage JL. A Health Policy Perspective on HighDose Cancer Therapy: Cost, Effectiveness, and Cost-effectiveness. in Armitage JO,
Antman KH. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells.
2nd Edition, William and Wilkins, Baltimore, MD 1995.
Brown P, Mettger W, Friedell G, Smith TJ. Incorporating Literacy into Research and
Practice. In Cancer and Literacy. JNCI Monograph, Bethesda, MD, 1995.
Hillner BE, Smith TJ. A short review of cost-effectiveness analysis of oncologic
treatments. In Hillman AL, Champey Y, Schwartz JS (eds) The Challenges in Studying
the Socioeconomic Dimensions in Cancer Therapy. The Medicine Group, Yardley, PA,
1995.
Loprinzi CL, Smith TJ*. Surveillance testing in curatively-treated cancer survivors.
ASCO Educational Symposium, Fall 1996 Education Book, ASCO, Alexandria, VA.
Smith TJ, Yanovich S, Hillner BE. Costs of high dose chemotherapy and blood/marrow
stem cell transplantation. In Lister J, Ball T. Bone Marrow Transplantation. Churchill
Livingstone, in press.
Smith TJ. Health service studies in the terminally ill cancer patient. In Bennett CL (ed)
Cancer Policy, Kluwer Academic Publishers. 1998.
Smith TJ. End of life care: preserving quality and quantity of life in managed care. In
Perry MC (Ed) American Society of Clinical Oncology Educational Book, American
Society of Clinical Oncology, Alexandria, VA, 1997. pp 303-307.
Smith TJ. Health care economics of palliative therapy. Springer Verlag, Tokyo, in press,
1998.
Bennett CL, Hillner BE, Smith TJ. "Economic Analysis of Cancer Care" in Abeloff MA,
Armitage JO, Lichter AS, Neiderhuber JE (eds) Clinical Oncology 2nd Edition,
Churchill Livingstone, 2000.
Lyckholm LL,*Smith TJ. Economic outcomes and palliative care. In Bruera E, Portenoy
RK (eds) Topics in Palliative Care, Oxford University Press, 2001.
Smith TJ. The role of G and GM-CSF in clinical practice. In American Society of
Clinical Oncology 1999 Educational Book, Alexandria, VA. 1999.
12.3.18 Lyckholm LL,*Smith TJ. Allocation of cancer care resources by effectiveness and cost
effectiveness. In, National Cancer Control Programmes; Policies and Managerial
Guidelines. WHO, in press.
12.3.19 Smith TJ. Designing model health care systems to provide cost-effective care. In Cancer
Survivorship Throughout the Life Span. New Jersey Commission on Cancer Research.
12.3.20 Hackney MH, Lyckholm L, Simonson CJ, Smith TJ*. Ethics of rural health care. For
Cancer Research and Treatment, Geneva, Switzerland, 1999.
12.3.21 Smith TJ, Staats P, Catala E, Pousa L, Pericai E, Buchser E, Perey L. Randomized
comparison of Medtronic intrathecal drug delivery systems (IDDS) plus comprehensive
medical management (CMM) vs. CMM for unrelieved cancer pain, Hamburg, Germany,
2000 (Annals of Oncology, 11:145, 2000).
12.3.22 Hackney MH, Simonson CJ, Overmeyer K, Brigle K, Cragg L, Shaw J, Sismanis A,
Lyckholm L and Smith TJ. Cancer Education through a Rural Cancer Outreach
Program. American and European Association of Cancer Education Joint Meeting,
November 2-5, 2000, Washington, DC (Journal of Cancer Education - Supplement to
Vol 15, 2000)
12.3.23 Thomas J. Smith, M.D. "The Usefulness of Utility in Making in Decisions About
Palliative Care," in Portenoy R (ed) "Proceedings of the NIH Conference on Palliative
Care Research: Issues in Palliative Care Research." In press, 2002
12.3.24 Smith TJ, Heddinger S. Medically appropriate Follow up of the patient with breast and
lung cancer: evidence based approach. ASCO Educational Book, 2002.
12.3.25 Smith TJ. Cost in palliative care. Panke,J. T. & Coyne, P. (2003) Conversations in
Palliative Care. Pensacola,FL: Pohl Publishing.
12.3.26 Lunney G, Foley KM, Smith TJ, Gelband H. Describing Death in America: What We
Need to Know. National Academies Press, Washington DC. 2003.
12.3.27 Khatcheressian J, Smith T. Economics of Cancer Care. In “Oncology, and evidence
based approach.” Springer, 2006.
12.3.28 Cassel JB, Smith T. “Cost avoidance and other financial outcomes for palliative care
programs” in Bruera E, Higginson I, Ripamonti C, vonGunten C. Textbook of Palliative
Care. Hodder Arnold, 2006.
12.4
Other - reviews, exhibits, films, tapes, etc.
12.4.1 Smith T: The Use of Conditional Discriminators in a Medical Audit. Medical doctorate
thesis, Yale University School of Medicine, 1979.